Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.40
-8.0%
$0.44
$0.29
$3.53
$59.10M2.219.25 million shs1.69 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$8.88
+12.8%
$5.03
$3.90
$15.00
$109.36M0.52219,361 shs726,897 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.12
-3.0%
$1.18
$0.79
$45.50
$18.17M1.46.79 million shs486,126 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.03
-5.1%
$1.10
$0.88
$2.57
$66.98M1.03720,224 shs333,557 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%-9.67%-5.06%-83.56%-77.02%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+40.82%+56.44%+74.78%-38.66%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%+4.55%-12.21%+16.40%-88.83%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%+1.89%-6.90%+2.86%-24.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.40
-8.0%
$0.44
$0.29
$3.53
$59.10M2.219.25 million shs1.69 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$8.88
+12.8%
$5.03
$3.90
$15.00
$109.36M0.52219,361 shs726,897 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.12
-3.0%
$1.18
$0.79
$45.50
$18.17M1.46.79 million shs486,126 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.03
-5.1%
$1.10
$0.88
$2.57
$66.98M1.03720,224 shs333,557 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%-9.67%-5.06%-83.56%-77.02%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+40.82%+56.44%+74.78%-38.66%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%+4.55%-12.21%+16.40%-88.83%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%+1.89%-6.90%+2.86%-24.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.75
Reduce$5.501,261.39% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-38.80% Downside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
1.71
Reduce$65.005,576.86% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.33
Hold$6.00476.92% Upside

Current Analyst Ratings Breakdown

Latest QNCX, IMMP, LFVN, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
5/1/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
DowngradeSell (D-)Sell (E+)
4/21/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Reiterated RatingSell (D-)
3/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
Reiterated RatingHold (C)
3/13/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
DowngradeBuyHold
3/13/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
DowngradeOutperformNeutral$7.00 ➝ $1.00
3/13/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
DowngradeOutperformMarket Perform
3/5/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Boost Price TargetOutperform$4.00 ➝ $5.00
(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$6.69M8.90N/AN/A$0.63 per share0.64
Lifevantage Corporation stock logo
LFVN
Lifevantage
$195.32M0.53$1.14 per share7.16$2.75 per share2.97
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A($6.41) per shareN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$10.32M6.59N/AN/A$2.16 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$39.78MN/AN/AN/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4518.1212.57N/A2.94%23.89%12.47%N/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$83.98M-$10.62N/AN/AN/AN/A-372.88%-67.99%8/11/2026 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%8/11/2026 (Estimated)

Latest QNCX, IMMP, LFVN, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$1.30-$0.59+$0.71$2.88N/AN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
5/6/2026Q1 2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million
3/4/2026Q4 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.27-$0.18+$0.09-$0.18$2.44 million$2.57 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.202.45%N/A44.44%3 Years
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A

Latest QNCX, IMMP, LFVN, and TCRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.44%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
2.97
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/A
2.92
2.92
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.34
6.65
6.65

Institutional Ownership

CompanyInstitutional Ownership
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
7.10%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021147.37 million142.85 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6016.30 million15.14 millionOptionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10065.35 million61.27 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$0.40 -0.03 (-7.95%)
As of 02:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$8.88 +1.01 (+12.82%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.12 -0.04 (-3.04%)
As of 02:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.02 -0.06 (-5.09%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.